Baseline characteristics and transplantation outcomes based on the CD34+ cell dose
| Characteristic∗ . | <4†, n = 56 . | 4-6†, n = 157 . | ≥6-8†, n = 46 . | ≥8†, n = 77 . | Missing, n = 39 . | P value . |
|---|---|---|---|---|---|---|
| Recipient age at transplant, y | 52 (38, 61) | 54 (37, 64) | 58 (42, 65) | 58 (46, 66) | 51 (35, 60) | .11 |
| Donor age at transplant, y | 36 (25, 50) | 40 (29, 51) | 38 (32, 50) | 36 (27, 45) | 38 (31, 54) | .4 |
| Recipient sex, female | 22 (39%) | 61 (39%) | 20 (43%) | 35 (45%) | 15 (38%) | .9 |
| Conditioning regimen | < .0001 | |||||
| Bu/Cy | 11 (20%) | 43 (27%) | 6 (13%) | 19 (25%) | 1 (2.6%) | |
| TBI ± Flu/Cy, MAC | 17 (30%) | 40 (25%) | 4 (8.7%) | 14 (18%) | 25 (64%) | |
| TBI ± Flu/Cy, RIC | 23 (41%) | 60 (38%) | 32 (70%) | 42 (55%) | 10 (26%) | |
| Flu/Mel | 4 (7.1%) | 11 (7.0%) | 1 (2.2%) | 1 (1.3%) | 2 (5.1%) | |
| Other | 1 (1.8%) | 3 (1.9%) | 3 (6.5%) | 1 (1.3%) | 1 (2.6%) | |
| HCT-CI | .78 | |||||
| 0 | 9 (16%) | 22 (14%) | 4 (8.7%) | 12 (16%) | 1 (2.6%) | |
| 1-2 | 15 (27%) | 40 (25%) | 17 (37%) | 23 (30%) | 12 (31%) | |
| 3+ | 32 (57%) | 91 (58%) | 24 (52%) | 42 (55%) | 25 (64%) | |
| Missing | 0 (0%) | 4 (2.5%) | 1 (2.2%) | 0 (0%) | 1 (2.6%) | |
| DRI | .99 | |||||
| Low | 4 (7.1%) | 12 (7.6%) | 2 (4.3%) | 6 (7.8%) | 4 (10%) | |
| Intermediate | 28 (50%) | 78 (50%) | 25 (54%) | 34 (44%) | 18 (46%) | |
| High/very high | 22 (39%) | 60 (38%) | 17 (37%) | 35 (45%) | 15 (38%) | |
| Missing | 2 (3.6%) | 7 (4.5%) | 2 (4.3%) | 2 (2.6%) | 2 (5.1%) | |
| KPS | .02 | |||||
| 90-100 | 24 (43%) | 83 (53%) | 24 (52%) | 34 (44%) | 7 (18%) | |
| ≤80 | 31 (55%) | 71 (45%) | 21 (46%) | 42 (55%) | 32 (82%) | |
| Missing | 1 (1.8%) | 3 (1.9%) | 1 (2.2%) | 1 (1.3%) | 0 (0%) |
| Characteristic∗ . | <4†, n = 56 . | 4-6†, n = 157 . | ≥6-8†, n = 46 . | ≥8†, n = 77 . | Missing, n = 39 . | P value . |
|---|---|---|---|---|---|---|
| Recipient age at transplant, y | 52 (38, 61) | 54 (37, 64) | 58 (42, 65) | 58 (46, 66) | 51 (35, 60) | .11 |
| Donor age at transplant, y | 36 (25, 50) | 40 (29, 51) | 38 (32, 50) | 36 (27, 45) | 38 (31, 54) | .4 |
| Recipient sex, female | 22 (39%) | 61 (39%) | 20 (43%) | 35 (45%) | 15 (38%) | .9 |
| Conditioning regimen | < .0001 | |||||
| Bu/Cy | 11 (20%) | 43 (27%) | 6 (13%) | 19 (25%) | 1 (2.6%) | |
| TBI ± Flu/Cy, MAC | 17 (30%) | 40 (25%) | 4 (8.7%) | 14 (18%) | 25 (64%) | |
| TBI ± Flu/Cy, RIC | 23 (41%) | 60 (38%) | 32 (70%) | 42 (55%) | 10 (26%) | |
| Flu/Mel | 4 (7.1%) | 11 (7.0%) | 1 (2.2%) | 1 (1.3%) | 2 (5.1%) | |
| Other | 1 (1.8%) | 3 (1.9%) | 3 (6.5%) | 1 (1.3%) | 1 (2.6%) | |
| HCT-CI | .78 | |||||
| 0 | 9 (16%) | 22 (14%) | 4 (8.7%) | 12 (16%) | 1 (2.6%) | |
| 1-2 | 15 (27%) | 40 (25%) | 17 (37%) | 23 (30%) | 12 (31%) | |
| 3+ | 32 (57%) | 91 (58%) | 24 (52%) | 42 (55%) | 25 (64%) | |
| Missing | 0 (0%) | 4 (2.5%) | 1 (2.2%) | 0 (0%) | 1 (2.6%) | |
| DRI | .99 | |||||
| Low | 4 (7.1%) | 12 (7.6%) | 2 (4.3%) | 6 (7.8%) | 4 (10%) | |
| Intermediate | 28 (50%) | 78 (50%) | 25 (54%) | 34 (44%) | 18 (46%) | |
| High/very high | 22 (39%) | 60 (38%) | 17 (37%) | 35 (45%) | 15 (38%) | |
| Missing | 2 (3.6%) | 7 (4.5%) | 2 (4.3%) | 2 (2.6%) | 2 (5.1%) | |
| KPS | .02 | |||||
| 90-100 | 24 (43%) | 83 (53%) | 24 (52%) | 34 (44%) | 7 (18%) | |
| ≤80 | 31 (55%) | 71 (45%) | 21 (46%) | 42 (55%) | 32 (82%) | |
| Missing | 1 (1.8%) | 3 (1.9%) | 1 (2.2%) | 1 (1.3%) | 0 (0%) |
Bu, busulfan; cy, cyclophosphamide; DRI, disease risk index; flu, fludarabine; GRFS, GVHD relapse-free survival; HCT-CI, hematopoietic cellular transplantation comorbidity index; KPS, Karnofsky performance status; MAC, myeloablative conditioning; mel, melphalan; OS, overall survival; RIC, reduced intensity conditioning; TBI, total body irradiation.
n (%); median (interquartile range).
All cell doses listed as ×106 CD34+ cells per kg recipient weight.